Corporate Profile

Intrexon Corporation, founded in 1998, is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment and Consumer sectors to create biologically based products that improve quality of life and the health of the planet. At present rates of global industrialization and population growth, food and energy supplies and environmental and healthcare resources are becoming scarcer. We believe Intrexon’s leading Better DNA® approach to synthetic biology has the potential to provide new, more effective and sustainable solutions to address these challenges. 

With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. Working with key collaborators, Intrexon seeks to develop high value applications that can bring better medicines to more people, alleviate shortages of essential nutrients, develop renewable fuels and other resources, and protect the environment.

AquaBounty Distribution
Recent Press Releases
Jan 19, 2018

Intrexon Corporation (NYSE: XON) announced today the closing of its previously announced underwritten public offering of common stock. Intrexon sold 6,900,000 shares of its common stock at a...

Jan 17, 2018

Intrexon Corporation (NYSE: XON) announced today that it has priced its previously announced underwritten public offering of common stock consisting of 6,000,000 shares at a public offering price...

Jan 16, 2018

Intrexon Corporation (NYSE: XON) announced today it has commenced an underwritten public offering of shares of its common stock. In addition, Intrexon intends to grant the underwriters a 30-day...

Jan 4, 2018

ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of...

More >>

Investor Contact

Thomas Shrader, PhD
Vice President, Communications & Strategy
Intrexon Corporation
investors@intrexon.com

 


print email